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Abstract
Background: Advances in genetic technologies are expected to make population-wide genetic testing feasible.
This could provide a basis for risk stratified cancer screening; but acceptability in the target populations has not
been explored.
Methods: We assessed attitudes to risk-stratified ovarian cancer (OC) screening based on prior genetic risk assessment
using a survey design. Home-based interviews were carried out by the UK Office of National Statistics in a
population-based sample of 1095 women aged 18–74. Demographic and personal correlates of attitudes to
risk-stratified OC screening based on prior genetic risk assessment were determined using univariate analyses
and adjusted logistic regression models.
Results: Full data on the key analytic questions were available for 829 respondents (mean age 46 years; 27 %
‘university educated’; 93 % ‘White’). Relatively few respondents felt they were at ‘higher’ or ‘much higher’ risk
of OC than other women of their age group (7.4 %, n = 61). Most women (85 %) said they would ‘probably’
or ‘definitely’ take up OC genetic testing; which increased to 88 % if the test also informed about breast
cancer risk. Almost all women (92 %) thought they would ‘probably’ or ‘definitely’ participate in risk-stratified
OC screening. In multivariate logistic regression models, university level education was associated with lower
anticipated uptake of genetic testing (p = 0.009), but with more positive attitudes toward risk-stratified
screening (p <0.001). Perceived risk was not significantly associated with any of the outcome variables.
Conclusions: These findings give confidence in taking forward research on integration of novel genomic
technologies into mainstream healthcare.
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Background
Although ovarian cancer is one of the leading causes of
cancer death in women [1], population-based screening
is not currently recommended because reliable early
risk-markers have not yet been identified [2–4]. For ex-
ample, the Prostate, Lung, Colorectal and Ovarian (PLCO)
Cancer Screening Trial demonstrated that current tests
(transvaginal ultrasound and CA-125) aimed at detecting
ovarian cancer early enough to reduce mortality were
ineffective. Further, results from this trial showed that
current risk profiling methods did not result in reduced
OC mortality when applied retrospectively to PLCO [5].
However, improved discrimination on the basis of genetic
predisposition to ovarian cancer, alongside increasing
affordability of genome sequencing, may improve
identification of ‘at-risk’ individuals. Focusing screen-
ing on women at the highest genetic risk would avoid
the risk of false positives for those at lower risk, and
could make ovarian cancer screening feasible and
cost-effective in the near future [6].
Currently, efforts are under way to develop and validate
models for risk stratification, early detection and diagnosis
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of OC which incorporate clinical, epidemiological, prote-
omic and genetic data (PROMISE 2016 ‘Predicting Risk of
Ovarian Malignancies, Improved Screening and Early
Detection’). Genetic models will include high penetrance
genes associated with hereditary breast and ovarian can-
cer, BRCA1 and BRCA2, as well as lower penetrance
genes associated with ovarian cancer susceptibility BRIP1,
RAD51C and RAD51D [7–9]. Given the 10 % risk of
ovarian cancer associated with Lynch syndrome [10],
mismatch repair genes MLH1, MSH2, MSH6 and
PMS2 will be included. The model could be modified
should other relevant genes be identified. The model
will also include clinical and epidemiological data
(family history, environmental, hormonal and reproduct-
ive factors). A workstream dedicated to proteomics aims
to identify novel early indicators of OC to improve on
current predictive values of CA-125. Women participating
in the programme will receive an estimation of OC risk
(low, intermediate or high). Women will be offered risk
stratified information, support and clinical intervention
(screening or surgery) depending on their personal risk.
However, the success of any cancer screening
programme depends on its acceptability in the target
population [11]. Given that early research indicates that
population-based genetic testing may improve current
family history based risk prediction approaches in a
cost-effective manner [12–14] it is timely to assess pub-
lic attitudes on this topic. Negative attitudes towards
population-based genetic testing would render the gen-
etic stratification approach unsuitable for existing or
new cancer screening programmes. Few studies have in-
vestigated attitudes to genetic testing for cancer risk in
general population samples. A review of studies carried
out in the United States found positive attitudes towards
predictive genetic testing for cancer, with anticipated up-
take of testing of over 70 %; although actual uptake has
been found to be somewhat lower [15]. A qualitative
study in the UK investigated attitudes to risk-stratified
ovarian cancer screening that incorporated genetic risk
assessment, and found that women were very positive
about it [16]. Similarly, a qualitative study in the
Netherlands reported positive attitudes towards amend-
ing the current breast cancer screening programme to
include risk-stratification based on genetic risk; with the
proviso that women who wanted to access screening
despite having low genetic risk could still do so [17].
However, because these samples were small, the findings
cannot be generalised to the wider population.
Research investigating the predictors of interest in
cancer genetic testing has predominantly focused on in-
dividuals with a strong family history of cancer. In these
studies, age, ethnicity and perceived risk have frequently
been shown to be associated with higher interest in test-
ing [15]. However, because of the psychological and
health implications of a strong family history of cancer,
these results cannot be assumed to generalise to the
wider population.
The aims of the present study were therefore to explore
public attitudes of women in the UK towards risk-stratified
screening based on prior genetic risk assessment for OC,
and identify demographic and personal predictors of antici-
pated uptake of both genetic testing and screening.
Methods and procedure
Sample
Data were collected as a part of the Office of National
Statistics (ONS) ‘Opinions and Lifestyle’ survey in January
and March 2014. This is a population-based survey of
adults aged 16–94 years conducted by the ONS on behalf
of government departments, non-governmental agencies,
and academic institutions. The sample covers Great
Britain (England, Wales and Scotland), excluding the
Isles of Scilly and the Scottish Highlands and Islands.
Modules include a range of topics; minimizing the
risk of respondent bias for specific topics. Respon-
dents are given the option to withdraw at any time.
Each month, households (n = 2010) are identified from the
Royal Mail’s Postcode Address File using stratified random
probability sampling. The selected addresses are contacted
up to eight times at different times and days of the week
to maximize response rates. One person aged over 16
from each household is randomly chosen to complete a
computer-assisted, face-to-face interview with a trained
interviewer. Verbal informed consent was obtained from
participants before commencing the survey. Since this
study was a population-based anonymous survey, it was
exempt from ethical approval, as per guidelines set out by
the UCL Ethics committee for non-NHS research (http://
ethics.grad.ucl.ac.uk/exemptions.php).
The genetic testing/screening module for this study
was introduced with a brief statement about the ques-
tions and a brief introduction to the topic: ‘The next set
of questions is about genes and cancer. The first questions
are about genes. Genes contain the ‘instruction manual’
of life, called DNA. Genes are passed from parents to
their children. Nowadays, it is possible to predict whether
someone is likely to develop certain diseases by looking at
their genes. This is called genetic testing.’
Measures
Outcome variables
The attitude items were specifically developed for this
survey. The questions were read aloud, but we used the
Flesch Reading Ease formula and the Flesch-Kincaid
Grade Level formula to provide a formal estimate of com-
prehension (https://readability-score.com/). This produced
a total score of 68 for all questions, which translates to the
reading level expected in grade 6 (age 12).
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Three questions addressed anticipated uptake of gen-
etic testing in the National Health Service (NHS). The
NHS is the provider of healthcare in the UK. The NHS
runs all the organised cancer screening programmes. Re-
sponse options for all questions were: ‘no, definitely not’;
‘no probably not’; ‘yes, probably’ and ‘yes, definitely’.
 ‘If the NHS offered a genetic test for the risk of
ovarian cancer, would you take up the offer’?
 ‘If the genetic test for ovarian cancer also told you about
your risk of breast cancer, would you take up the offer’?
 ‘A small number of women may be found to be at
very high risk when they have the genetic test. They
would be offered surgery to have their ovaries removed.
Considering that your genetic test result might mean
you are offered surgery to remove your ovaries, would
you still take up the offer of a genetic test’?
Two questions addressed attitudes to risk-stratified
ovarian cancer screening:
 ‘If you were invited for NHS screening for ovarian
cancer, would you take up the offer’ (‘no, definitely
not’; ‘no probably not’; ‘yes, probably’; ‘yes,
definitely’)?
 ‘It’s possible that women who are found to be at
higher genetic risk will be offered more frequent
screening for ovarian cancer, and those found to be
at lower risk will be offered less frequent screening.
What do you think of the idea of varying the
frequency of ovarian screening’ (‘very bad idea’; ‘bad
idea’; ‘not sure’; ‘good idea’ and ‘very good idea’)?
Perceived relative risk of ovarian cancer was assessed
with one question: ‘Compared with other women of your
age, what do you think are your chances of getting ovar-
ian cancer’? Response options were: ‘much lower than
others’, ‘lower than others’, ‘the same as others’, ‘higher than
others’, ‘much higher than others’. For the current ana-
lyses, the first three and last two categories were com-
bined to reflect lower/average vs. higher perceived risk.
Demographic data were provided by ONS from their
standard survey items (http://www.ons.gov.uk/ons/
index.html). Age was included as a continuous variable in
statistical analyses. Ethnicity was classified as ‘White’ vs.
‘Ethnic minority’ because the individual ethnic minority
sub-groups were small; making subdivision inappropriate.
Educational attainment was classified as university degree
or equivalent vs. below degree level. Marital status was
coded as married/cohabiting vs. single/widowed/divorced.
Statistical analyses
We only included women age 18–74 years to reflect the
population to whom ovarian cancer screening might be
offered. We excluded participants who had missing data
for any of the variables in the analyses.
Statistical analyses were carried out using the Statis-
tical Package for Social Sciences (SPSS) version 20.0
(SPPS Inc., Chicago, IL). Univariate χ2 analyses were
used to explore demographic predictors and the impact
of perceived risk on each dichotomous outcome variable.
Multivariate logistic regression was used to establish
the associations with: i) the three items on anticipated
uptake of genetic testing, and ii) the two items on
attitudes to risk-stratified screening. The first model
included only demographic characteristics, and the
second one added perceived risk. Bonferroni correc-
tions were used to correct for multiple testing, so α
was set at 0.05/5 = 0.01.
Results
Data for the current study were collected in two waves:
January and March 2014. In the January wave, 8 % (n =
166) of the 2010 selected households were not eligible
because they were businesses or empty properties. Of
1844 eligible households, 9 % (n = 171) could not be
contacted and 33 % (n = 608) declined to take part in the
ONS survey. In the March wave, 8 % (165) of selected
households were not eligible because they were business
or empty properties. Of the 1853 eligible households,
13 % (n = 237) could not be contacted and 31 % (n =
578) chose not to take part. Therefore, the overall re-
sponse rate was 57 %, comparable to previous ONS
surveys (http://tinyurl.com/z8apjt6). The total female
sample was n = 1095.
Sample characteristics
After exclusion of individuals who were ineligible due to
age (n = 138) or missing data (n = 128), the final sample
for analysis consisted of 829 women aged 18–74 (mean
46 years; SD = 15.5 years). Most were ‘White’ (92.9 %,
n = 770), just over half were married or cohabiting
(54.8 %, n = 454), and just over a quarter (27.3 %, n = 226)
were at least university educated. With the exception of
education, which was higher in this sample, demographic
characteristics were comparable to the UK female
population in this age group (ONS Census 2011:
http://www.ons.gov.uk/ons/guide-method/census/2011/
uk-census/uk-census-data-releases/index.html).
Anticipated uptake of genetic testing for ovarian cancer
Overall, interest in genetic testing for ovarian cancer
was very high. Most women said they would ‘probably’
or ‘definitely’ take up an offer of genetic testing (84.9 %,
n = 734), which increased to 88.3 % (n = 819) if the test
also informed about breast cancer risk. Anticipated
‘probable’ or ‘definite’ uptake remained high (85.7 %,
n = 787) if the test result indicated they were at very
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high risk and the appropriate risk management rec-
ommendation was risk-reducing surgery.
There were few demographic differences in anticipated
uptake of genetic testing for ovarian cancer risk (Table 1).
Ethnic minority status was associated with lower antici-
pated uptake of genetic testing only if it involved a
potential offer of surgery in univariate analyses. Table 2
shows that the association remained significant in
Bonferroni corrected logistic regression models after
adjusting for all other demographic and personal
variables (OR = 2.14, 95 % CI = 1.25-3.66, p = 0.006).
University level education was not associated with an-
ticipated uptake of genetic testing in univariate analyses,
but it became significantly associated with lower antici-
pated uptake once demographic and personal factors
were taken into account (OR = 0.67, 95 % CI = 0.49-
0.94, p = 0.009).
The impact of perceived personal risk on anticipated
uptake of genetic testing
Relatively few participants felt that they were at ‘higher’
or ‘much higher’ risk of ovarian cancer than other
women of their age group (7.4 %, n = 61). Perceived risk
was not significantly associated with anticipated uptake
of ovarian cancer genetic testing in univariate analyses
(p = 0.729), and adding it to the multivariate model made
no difference to the other associations (data not shown).
Anticipated uptake of, and attitudes to, risk-stratified
screening for ovarian cancer
Anticipated uptake of ovarian cancer screening was
also very high, with 92.3 % of women reporting that
they would ‘probably’ or ‘definitely’ take up ovarian
cancer screening if invited. Over two thirds of the
sample would support risk-stratified ovarian cancer
screening (66.6 %).
There were few demographic associations with an-
ticipated uptake of ovarian screening or attitudes to
risk-stratified screening. University level education
was associated with more positive attitudes towards
risk-stratified screening in univariate and multivariate
analyses (multivariate OR = 2.22, 95 % CI = 1.57-3.14,
p <0.001).
The impact of perceived risk on anticipated uptake of,
and attitudes to, risk-stratified screening for ovarian
cancer
Perceived risk was not significantly associated with
anticipated uptake of ovarian cancer screening in univar-
iate analyses (p = 0.882). Slightly more respondents who
perceived themselves as higher risk than lower risk sup-
ported risk-stratified screening (69.8 % vs. 67.3 %), but
the difference was not significant (p = 0.685). Perceived
risk was also not significantly associated with any of out-
comes in multivariate models (data not shown).
Table 1 Univariate analyses of anticipated uptake of genetic testing for ovarian cancer risk
Variable Probable/definite uptake
of OC genetic testing if
offered by NHS
Probable/definite uptake
of OC genetic testing if it
also informs about BC risk
Probable/definite uptake
of OC genetic testing with
potential for surgery
Probable/definite
uptake of
OC screening
Good/very good idea
to vary frequency of
OC screening by risk
% Total (N = 829) 84.1 88.1 85.6 92.3 66.6
Mean Age (SD) 46.9 (15.6) 46.6 (15.2) 48.1 (15.1) 46.9 (15.2) 46.8 (15.4)
Ethnicity
% Ethnic minority 85.2 83.6 72.6** 91.8 59.0
% White 84.0 88.6 86.5 92.6 67.3
Education
% Below university 84.3 86.9* 84.5 91.6 62.4**
% University 84.0 92.0 89.0 95.2 78.6
Marital status
% Married/cohabiting 85.0 89.6 83.9 93.6 68.3
% Single/widowed/
divorced
83.3 86.7 87.3 91.4 65.0
Perceived risk of ovarian cancer
% Much lower/lower/
the same as others
84.1 88.0 84.9 92.6 67.3
% Higher/much
higher than others
85.7 90.5 90.2 92.1 69.8
Abbreviations: OC ovarian cancer, BC breast cancer, NHS National Health Service, the provider of healthcare and organised screening in the UK; * p <0.05;
** p <0.01
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Discussion
This is the first quantitative study of attitudes to
population-based genetic testing with subsequent risk-
stratified screening for ovarian cancer screening. Al-
though the scenarios used in the survey were somewhat
hypothetical since OC screening is currently not recom-
mended, the results show high levels of support for
stratified cancer screening based on prior genetic risk as-
sessment, with little variation across demographic and
personal characteristics.
Similar to earlier qualitative studies, [16, 17] most sur-
vey respondents were enthusiastic about a risk-stratified
approach to screening, and over two thirds would sup-
port it. However, supporters were more likely to hold a
university degree than those more sceptical of risk-
stratified screening. It is possible that less educated
respondents felt less knowledgeable about the concept
of personalized screening, and therefore less certain of
benefits and disadvantages. Future work could explore
the reasons behind this finding to address any informa-
tion needs and concerns early on. Age was not associ-
ated with attitudes towards risk-stratified screening
which suggests that personal experience of breast cancer
screening may not overly influence attitudes. However,
overall, these results suggest slightly more openness to
risk stratified screening than described by Henneman
and colleagues [17] in the Dutch sample. It is possible
that introduction of a new risk-stratified screening
programme is met with less resistance than the prospect
of amending an existing cancer screening programme,
and this hypothesis could be explored in future research.
Ethnic minority status was associated with less positive
attitudes towards OC genetic testing only if it involved
the potential offer of surgery to have the ovaries removed.
This suggests that factors other than the prospect of gen-
etic testing per se may be important contributors to the
decision of whether to undergo genetic testing. However,
because we had to combine women from all ethnic
subgroups because individual subgroups were small –
approximating population levels – the current findings
should be viewed with caution. Future qualitative research
could investigate attitudes towards genetic testing in
women from ethnic minority subgroups further.
Although perceived risk has often been described as
an important predictor of both anticipated and actual
uptake of genetic testing and screening, [18–20] we did
not find significant associations with attitudes to genetic
testing or risk-stratified screening. Differences in the
measure of perceived risk may contribute to the differ-
ence; earlier studies assessed absolute risk perception
which may result in an overestimation of risk, whereas
we assessed perceived relative risk in the current study,
which has been shown to be more robust [21, 22]. How-
ever, it is also possible that the widespread use of single
item measures reduces the reliability of the results, espe-
cially where the proportion of women who perceive
themselves to be at high risk is low – as was the case in
this study.
In the present study interest in genetic testing was
very high despite few women perceiving their risk as
high. This suggests that women would choose to
undergo genetic testing for reasons other than perceived
high personal risk of ovarian cancer. One possibility
is that they have altruistic motives; wanting to obtain
information for their children and families, as sug-
gested by findings from studies concerned with
Table 2 Multivariate logistic regression of demographic predictors of anticipated uptake of genetic testing for ovarian cancer risk
Variable Probable/definite uptake
of OC genetic testing if
offered by NHS
Probable/definite
uptake of OC genetic
testing if it also informs
about BC risk
Probable/definite uptake
of OC genetic testing
with potential for surgery
Probable/definite
uptake of OC screening
if offered by the NHS
Good/very good idea
varying frequency of
OC cancer screening
by personal risk
N = 829 OR 95 % CI p-value OR 95 % CI p-value OR 95 % CI p-value OR 95 % CI p-value OR 95 % CI p-value
Age (trend) 0.99 0.98-1.02 0.153 0.99 0.98-1.00 0.081 1.01 1.00-1.01 0.028 1.00 0.99-1.00 0.924 1.00 0.99-1.01 0.881
Ethnicity
Ethnic minority 1 1 1 1 1
White 1.67 0.98-2.83 0.057 1.62 0.95-2.75 0.073 2.14 1.25-3.66 0.006 1.85 1.06-3.23 0.028 1.51 0.87-2.60 0.136
Education
Below university 1 1 1 1 1
University 0.67 0.49-0.94 0.009 0.76 0.56-1.03 0.078 0.93 0.69-1.27 0.938 1.15 0.88-1.79 0.204 2.22 1.57-3.14 <0.001
Marital status
Sgl/wid/div 1 1 1 1 1
Married/cohab 1.24 0.95-1.62 0.103 1.06 0.80-1.39 0.664 1.41 1.08-1.84 0.012 1.35 1.00-1.83 0.050 1.08 0.82-1.43 0.568
Abbreviations: Sgl single, wid widowed, div divorced, cohab cohabiting
Analyses are mutually adjusted for age (modelled as continuous variable), ethnicity, education and marital status (modelled as binary variables)
BOLD significant after adjustment for multiple testing p < 0.01
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uptake of personal genomic testing [23, 24]. Alterna-
tively, they may want to obtain the information for its
own value, or because they self-identify as an
information-seeker [25]. Characterising reasons for
taking part in genetic testing without significant family
history and low perceived risk of ovarian cancer will be
important because they may influence subsequent reac-
tions to the test results.
This study had some strengths. The question module
was included in a large monthly survey conducted by an
external agency (ONS) which reduces the likelihood of
response bias related to the specific subject matter. The
sample had been recruited by stratified random sampling
which is the ‘gold-standard’ of survey recruitment; there-
fore, it is broadly representative of the UK population of
women aged 18–74. We adjusted analyses for multiple
testing, which gives confidence in the robustness of the
current findings.
The study also had limitations. At this stage, neither
population-based genetic testing nor OC screening is
recommended. Therefore, all the questions alluded to
hypothetical scenarios rather than real testing/screening
offers, and these have been found to correlate only
modestly with actual behaviour [15, 26]. However, the
results are useful for gauging general attitudes to-
wards risk-stratified screening programme in a cost-
effective manner. Although the response rate was
comparable to other ONS surveys, there are a large
proportion of potential respondents whose views are
unknown, limiting generalizability of the findings.
However, refusal was for the survey in general, and
not for the specific module. All questions in this sur-
vey were ‘closed’, which prevented us exploring the
answers in more detail. Further qualitative research
could be useful to examine women’s thinking about
population-based genetic testing and risk-stratified
screening. Finally, this survey was conducted after the
well-known actress Angelina Jolie had publicly dis-
cussed her BRCA positive status and risk-reducing bi-
lateral mastectomy, which may have brought genetic
testing to the attention of the general population and
influenced attitudes [27–29].
Stratified cancer screening based on genetic risk is
considerably more complex than simple age-stratified
approaches and raises many ethical, legal, social and or-
ganisational aspects [30]. Chowdhury and colleagues
have outlined these in detail, including issues relating to
test sensitivity and specificity, effective risk communica-
tion, communication of incidental findings, potential for
discrimination, and the need for adequate preparation of
the healthcare workforce [31]. Despite these challenges,
it is interesting to see that public opinion of women in
the UK appears to support efforts to ‘personalize’ cancer
screening.
Conclusion
The findings from this study suggest that women in the
UK are ready to accept the introduction of population-
based genetic testing for personalisation of future cancer
screening programmes; giving confidence in taking for-
ward research on integration of novel genomic technolo-
gies into mainstream healthcare.
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